Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field

利用重组人甲状旁腺激素和电磁场治疗绝经后骨质疏松症

阅读:1

Abstract

OBJECTIVE: This study aimed to investigate the effect of electromagnetic field (EMF) combined with recombinant human parathyroid hormone (rhPTH) on bone mineral density (BMD) and bone turnover indicators in postmenopausal osteoporosis (PMOP) patients. METHODS: A total of 336 PMOP patients were randomly assigned into three groups: EMF + rhPTH group (n = 115), rhPTHx group (n = 113) and EMF group (n = 108). The lumbar spine and femoral neck BMDs were measured before treatment and at 6, 12, and 18 months after treatment. Blood calcium, bone alkaline phosphatase (BSAP), type I procollagen N-terminal peptide (PINP), and type I collagen C-terminal peptide/creatinine ratio (CTX/Cr) levels were measured before treatment and at 3, 6, 12, and 18 months after treatment. RESULTS: The lumbar spine BMD was significantly increased at 6, 12, and 18 months after treatment, and the neck BMD was increased markedly at 18 months in both EMF + rhPTH group and rhPTH group as compared to those before treatment. There was significant difference in the lumbar spine BMD between EMF + rhPTH group and EMF group and between rhPTH group and EMF group at 6, 12, and 18 months after treatment. In the EMF + rhPTH group, at 3, 6, 12, and 18 months after treatment, blood calcium level was increased by 5.2%, 2.8%, 2.7%, and 3.1%, respectively; BASP level was increased by 80.9%, 120.3%, 84.1%, and 67.7%, respectively; PINP level was increased by 65.4%, 79.7%, 89.7%, and 74.5%, respectively; CTX/Cr was increased by 80.9%, 120.3%, 84.1%, and 67.7%, respectively; the bone metabolism indicators were markedly higher than those before treatment. In the rhPTH group, at 3, 6, 12, and 18 months after treatment, blood calcium level was increased by 5.1%, 3.3%, 3.0%, and 2.1%, respectively; BSAP level was increased by 51.6%, 81.4%, 101.1% and 56.3% respectively; PINP level was increased by 48.5%, 69.8%, 80.7% and 70.5% respectively; CTX/Cr was increased by 29.8%, 29.9%, 55.7%, and 44.8% respectively; the bone turnover indicators were significantly different from those before treatment (P < 0.01). CONCLUSION: The combination of EMF and rhPTH can significantly improve the bone turnover and BMD of PMOP patients, and may serve as a clinical treatment of PMOP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。